These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 29447987)

  • 1. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).
    Winthrop KL; Mariette X; Silva JT; Benamu E; Calabrese LH; Dumusc A; Smolen JS; Aguado JM; Fernández-Ruiz M
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S21-S40. PubMed ID: 29447987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).
    Baddley JW; Cantini F; Goletti D; Gómez-Reino JJ; Mylonakis E; San-Juan R; Fernández-Ruiz M; Torre-Cisneros J
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S10-S20. PubMed ID: 29459143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).
    Redelman-Sidi G; Michielin O; Cervera C; Ribi C; Aguado JM; Fernández-Ruiz M; Manuel O
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2(Suppl 2):S95-S107. PubMed ID: 29427804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4).
    Drgona L; Gudiol C; Lanini S; Salzberger B; Ippolito G; Mikulska M
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S83-S94. PubMed ID: 29572070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction).
    Fernández-Ruiz M; Meije Y; Manuel O; Akan H; Carratalà J; Aguado JM; Delaloye J
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S2-S9. PubMed ID: 29427801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways).
    Aguilar-Company J; Fernández-Ruiz M; García-Campelo R; Garrido-Castro AC; Ruiz-Camps I
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S41-S52. PubMed ID: 29426804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52).
    Mikulska M; Lanini S; Gudiol C; Drgona L; Ippolito G; Fernández-Ruiz M; Salzberger B
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S71-S82. PubMed ID: 29447988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).
    Reinwald M; Silva JT; Mueller NJ; Fortún J; Garzoni C; de Fijter JW; Fernández-Ruiz M; Grossi P; Aguado JM
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S53-S70. PubMed ID: 29454849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editorial for ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective.
    Aguado JM; Manuel O
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S1. PubMed ID: 29803289
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
    Canavan TN; Elmets CA; Cantrell WL; Evans JM; Elewski BE
    Am J Clin Dermatol; 2016 Feb; 17(1):33-47. PubMed ID: 26649440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Therapeutic Approaches and Targets for Treatment of Psoriasis.
    Radi G; Campanati A; Diotallevi F; Bianchelli T; Offidani A
    Curr Pharm Biotechnol; 2021; 22(1):7-31. PubMed ID: 32598253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-17 inhibitors for psoriasis.
    Paek SY; Frieder J; Kivelevitch D; Menter MA
    Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: 'ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies' by Mikulska et al.
    Wijetilleka S; Jayne D; Mukhtyar C; Karim MY
    Clin Microbiol Infect; 2019 Apr; 25(4):531-532. PubMed ID: 30594651
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-IL-17 Agents for Psoriasis: A Review of Phase III Data.
    Farahnik B; Beroukhim K; Nakamura M; Abrouk M; Zhu TH; Singh R; Lee K; Bhutani T; Koo J
    J Drugs Dermatol; 2016 Mar; 15(3):311-6. PubMed ID: 26954316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions.
    Wu KK; Lee MP; Lee EB; Wu JJ
    J Dermatolog Treat; 2020 Jun; 31(4):359-365. PubMed ID: 30900514
    [No Abstract]   [Full Text] [Related]  

  • 17. No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents.
    Chiricozzi A; Romanelli M; Saraceno R; Torres T
    Expert Opin Drug Saf; 2016 Dec; 15(12):1653-1659. PubMed ID: 27554637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
    Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
    Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.
    Gooderham M; Posso-De Los Rios CJ; Rubio-Gomez GA; Papp K
    Skin Therapy Lett; 2015; 20(1):1-5. PubMed ID: 25807214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety of brodalumab for the treatment of psoriasis.
    Iznardo H; Puig L
    Expert Opin Drug Saf; 2020 Apr; 19(4):365-372. PubMed ID: 32053396
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.